Loss of UFL1 confers enzalutamide resistance of prostate tumors by regulating METTL16-mediated m6A modification of EEF1A1 mRNA
International Journal of Biological Sciences · 2026
DOI: 10.7150/ijbs.124214 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2026. Verfasst von Xu Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Benzamides, Nitriles, Phenylthiohydantoin. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Enzalutamide (ENZ), a next-generation androgen receptor (AR) inhibitor, is a cornerstone treatment for metastatic prostate cancer. However, resistance to ENZ inevitably develops in these patients, and the mechanisms underlying this resistance remain poorly understood. This study reveals that UFL1 is dysregulated in ENZ-resistant cells, xenograft models, and prostate tumors. UFL1 deficiency enhances prostate cancer cell resistance to ENZ both in vitro and in vivo. Mechanistically, UFL1 loss decreases METTL16 UFMylation, thereby reducing its ubiquitination level and increasing its protein stability. Additionally, METTL16-mediated m6A modification of EEF1A1 mRNA activates the m6A-IGF2BP1 axis, resulting in increased EEF1A1 protein levels and enhanced resistance to ENZ-induced apoptosis. These findings uncover a novel UFL1-METTL16-EEF1A1 signaling pathway that drives ENZ resistance, suggesting that targeting this cascade may offer a promising therapeutic strategy for overcoming ENZ resistance in prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei 230022, China.
- Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu, China.
- Department of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
- Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Zitieren
APA
Wu, X., Gao, H., Zhuang, Q., Li, F., Feng, X., Shao, N., Zhang, W., Zhang, Y., & Zhang, X. (2026). Loss of UFL1 confers enzalutamide resistance of prostate tumors by regulating METTL16-mediated m6A modification of EEF1A1 mRNA. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.124214
Vancouver
Wu X, Gao H, Zhuang Q, Li F, Feng X, Shao N, et al. Loss of UFL1 confers enzalutamide resistance of prostate tumors by regulating METTL16-mediated m6A modification of EEF1A1 mRNA. International Journal of Biological Sciences. 2026. doi:10.7150/ijbs.124214
BibTeX
@article{Wu2026,
author = {Wu, Xu and Gao, Hui and Zhuang, Qianfeng and Li, Feng and Feng, Xingliang and Shao, Naiyuan and Zhang, Wei and Zhang, Yuyang and Zhang, Xiansheng},
title = {Loss of UFL1 confers enzalutamide resistance of prostate tumors by regulating METTL16-mediated m6A modification of EEF1A1 mRNA},
journal = {International Journal of Biological Sciences},
year = {2026},
doi = {10.7150/ijbs.124214}
}
EUVIMED